Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05910528 · ClinicalTrials.gov registry record · Phase 2
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
A Phase 2 study of Crohn's Disease, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 11
- Study locations
NCT05910528: Active Phase 2 study of Crohn's Disease, sponsored by Hoffmann-La Roche.
NCT05910528 is a Phase 2 study of Crohn's Disease that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 21 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05910528, a Phase 2 study of Crohn's Disease, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 11
- Study locations
Study Summary
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
Conditions Studied
Interventions
- DRUG Afimkibart
Study Locations (11)
Other
- AZ Delta - Roeselare
- CHU de Nantes - Nantes
- Institut des MICI, Clinique Ambroise Paré - Neuilly-sur-Seine
- CHRU de Nancy Brabois - Vandœuvre-lès-Nancy
- Twoja Przychodnia-Szczecinskie Centrum Medyczne - Szczecin
- WIP Warsaw IBD Point Profesor Kierkus - Warsaw
Alabama
- Digestive Health Specialists - Dothan
Connecticut
- Medical Research Center of Connecticut, LLC - Hamden
Florida
- I.H.S Health Northwell Health - Kissimmee
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Clinical Research Institute of Michigan - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-07-24 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05910528 still lists
NCT05910528 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Afimkibart is the first listed.
NCT05910528 lists 11 locations in 6 states (Other, Alabama, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05910528 about?
NCT05910528 is a clinical study titled "Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease". This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.
What is the current status of trial NCT05910528?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2023-07-24. Estimated completion is 2030-12-31.
What conditions does trial NCT05910528 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT05910528?
The interventions under investigation include: Afimkibart (DRUG).
Who is sponsoring clinical trial NCT05910528?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05910528 being conducted?
This trial has 11 study locations across Alabama, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05910528's enrollment target sits among peer trials
21 98th of 105 higher than 8 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
RECRUITING · Phase 2
-
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
RECRUITING · Phase 2
-
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI